Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF inhalation to prevent ARDS in COVID-19 pneumonia
2020-001654-21Phase 2Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia comparing Molgramostim inhalation with Placebo inhalation (2 arms). Primary endpoint: Need for mechanical ventilation within 15 days after randomization. Started May 2020; status: completed.
02
Drugs
sargramostim
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001654-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001654-21.